EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Nanobody‐Conjugated Theranostic Prodrug Targeting α v β 3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang und 2 weitere

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202505197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Sanu Karan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center For Target-to-Therapeutics Research, Korea Basic Science Institute, Cheongju, Republic of Korea. Hauptthemen laut MEDLINE: Prodrugs, Integrin alphaVbeta3, Theranostic Nanomedicine, Single-Domain Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Basic Science Institute, National Research Council of Science & Technology (NST) grant from the Korea government, KEIT grant from the Korea government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Theranostic prodrugs that integrate diagnostic and therapeutic functionalities represent a promising avenue for precision oncology. In this study, we report the rational design, synthesis, and preclinical evaluation of a nanobody‐based α v β 3 integrin‐targeted theranostic prodrug ( NBD ). The system incorporates a glutathione‐responsive disulfide linker to enable selective release of doxorubicin within the tumor microenvironment, alongside an aza‐BODIPY near‐infrared fluorophore that providesactivatable imaging capability. Compared to its cRGD peptide‐conjugated counterpart ( cRBD ), NBD demonstrated superior tumor selectivity, intracellular activation, and cytotoxic potency in α v β 3 ‐overexpressing cancer cell lines. In vivo studies using SKOV3 xenograft models confirmed prolonged tumor retention, enhanced drug accumulation, and potent tumor suppression, with minimal systemic toxicity. Moreover, real‐time imaging enabled precise monitoring of prodrug activation and distribution. These findings highlight the unique advantages of nanobody‐guided theranostic platforms in enabling targeted drug delivery, reducing off‐target effects, and facilitating image‐guided therapy. The modular design of NBD provides a versatile framework for advancing personalized cancer treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsIntegrin alphaVbeta3Theranostic NanomedicineSingle-Domain AntibodiesNeoplasmsHumansAnimalsCell Line, TumorFemaleMiceDoxorubicinMice, NudeXenograft Model Antitumor Assays

Stichwörter der Autor:innen

nanobodynear‐infrared imagingprecision oncologytheranostic prodrugαvβ3 integrin

Substanzen

ProdrugsIntegrin alphaVbeta3Single-Domain AntibodiesDoxorubicin

Autor:innen und Institutionen

  • Center For Target-to-Therapeutics Research, Korea Basic Science Institute, Cheongju, Republic of Korea.
  • Immunology and Immunopharmacology Laboratory, College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
  • Department of Chemistry, Korea Advance Institute of Science and Technology, Daejeon, Republic of Korea.
  • Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea.
  • Department of Chemistry, Chung-Ang University, Seoul, Republic of Korea.
  • Department of Chemistry, The University of Texas at Austin, Austin, Texas, USA.

ORCID-Profile: Jonathan L Sessler, Kwan Soo Hong

Förderung

  • Korea Basic Science Institute
  • National Research Council of Science & Technology (NST) grant from the Korea government
  • KEIT grant from the Korea government
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Karan, S., Lee, H., Naskar, R., Cho, M. Y., Park, H. S., Han, E. H., Hore, S., Cho, S. H., Lam, T. N. K., Son, T., Park, T. J., Hwang, I., Sessler, J. L., & Hong, K. S. (2026). Nanobody‐Conjugated Theranostic Prodrug Targeting α v β 3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505197

Vancouver

Karan S, Lee H, Naskar R, Cho MY, Park HS, Han EH, et al. Nanobody‐Conjugated Theranostic Prodrug Targeting α v β 3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505197

BibTeX
@article{Karan2026,
  author = {Karan, Sanu and Lee, Hyunseung and Naskar, Rema and Cho, Mi Young and Park, Hye Sun and Han, Eun Hee and Hore, Soumyadip and Cho, Sun Hee and Lam, Truc Ngoc Kim and Son, Taewoong and Park, Tae Jung and Hwang, Inkyu and Sessler, Jonathan L and Hong, Kwan Soo},
  title = {Nanobody‐Conjugated Theranostic Prodrug Targeting α v β 3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202505197}
}
Kostenlos starten →